Javascript Disabled

This site requires Javascript in order to function properly. Please enable it in your browser's settings.

* Phosphorus reductions maintained for up to 3 years in patients remaining on therapy (n=46)1-3
  • FOSRENOL Chewable Tablets: Approved in 2004 and used in US clinical practices for more than a decade4,5 Learn more
  • FOSRENOL Oral Powder: Available since May 2015, offering you another approved administration option6 Learn more

Indication

FOSRENOL is indicated to reduce serum phosphate in patients with end stage renal disease (ESRD).

Please click here for Full Prescribing Information .

Important Safety Information

Indication

FOSRENOL is indicated to reduce serum phosphate in patients with end stage renal disease (ESRD).

Please click here for Full Prescribing Information.

References: 1. Hutchison AJ, Maes B, Vanwalleghem J, et al. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract. 2006;102:c61-c71. 2. Hutchison AJ, Maes B, Vanwalleghem J, et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract. 2005;100:c8-c19. 3. Data on file, Shire US Inc., SPD405-04. 4. Center for Drug Evaluation and Research. FOSRENOL approval letter. US Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/21468ltr.pdf. Accessed March 29, 2015. 5. Data on file, Shire US Inc., SPD405-031. 6. FOSRENOL [package insert]. Lexington, MA: Shire US Inc.